Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009951
Filing Date
2022-05-16
Accepted
2022-05-16 08:01:19
Documents
68
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q impl-20220331.htm   iXBRL 10-Q 2445302
2 EX-10.1 impl-ex10_1.htm EX-10.1 2958668
3 EX-10.2 impl-ex10_2.htm EX-10.2 1951707
4 EX-31.1 impl-ex31_1.htm EX-31.1 20053
5 EX-31.2 impl-ex31_2.htm EX-31.2 19820
6 EX-32.1 impl-ex32_1.htm EX-32.1 9638
7 EX-32.2 impl-ex32_2.htm EX-32.2 9713
  Complete submission text file 0000950170-22-009951.txt   13950117

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20220331.xsd EX-101.SCH 63635
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT impl-20220331_def.xml EX-101.DEF 209614
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT impl-20220331_cal.xml EX-101.CAL 44716
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20220331_pre.xml EX-101.PRE 381168
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20220331_lab.xml EX-101.LAB 529079
62 EXTRACTED XBRL INSTANCE DOCUMENT impl-20220331_htm.xml XML 1394037
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

EIN.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 10-Q | Act: 34 | File No.: 001-40353 | Film No.: 22925596
SIC: 2834 Pharmaceutical Preparations